TuisBNTC • NASDAQ
add
Benitec Biopharma Inc
Vorige sluiting
$8,67
Dagwisseling
$8,62 - $9,33
Jaarwisseling
$2,69 - $10,88
Markkapitalisasie
93,09Â m USD
Gemiddelde volume
18,07Â k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 4,14Â m | -5,71% |
Netto inkomste | -4,28Â m | 2,68% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -4,12Â m | 4,48% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 14,14Â m | 115,89% |
Totale bates | 15,00Â m | 82,47% |
Totale aanspreeklikheid | 3,50Â m | -0,23% |
Totale ekwiteit | 11,50 m | — |
Uitstaande aandele | 9,37 m | — |
Prys om te bespreek | 2,05 | — |
Opbrengs op bates | -56,96% | — |
Opbrengs op kapitaal | -74,62% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -4,28Â m | 2,68% |
Kontant van bedrywe | -6,17Â m | -53,09% |
Kontant van beleggings | -179,00 k | — |
Kontant van finansiering | 0,00 | — |
Netto kontantverandering | -6,23Â m | -56,35% |
Beskikbare kontantvloei | -4,60Â m | -100,03% |
Meer oor
Benitec Biopharma Limited is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference technology.
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research. Wikipedia
Gestig
1997
Webwerf
Werknemers
16
